About Contact Us Careers
Sign In

Methotrexate Drugs Market Trends

  • Report ID: 2738
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Global Methotrexate Drug Market TOC

 

  1. Market Definition
    1. Definition
    2. Market Segmentation
    3. Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. Suppliers/Distributors
      3. End-Users
    3. Secondary Research
    4. Market Size Estimation
  4. Analyst Review
  5. Executive Summary – Global Methotrexate Drug Market
  6. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Market Trends
    4. Opportunities
  7. Regulatory and Standards Landscape
    1. FDA
    2. WHO
    3. Others
  8. Industry Risk Analysis
  9. World Economic Outlook: Challenges for Global Recovery and its Impact on Global Methotrexate Drug Market
  10. Impact of COVID-19 on the Global Methotrexate Drug Market
  11. Epidemiology Analysis of Cancer and Rheumatoid Arthritis
  12. End-user analysis
  13. Industry Supply Chain Analysis
  14. Competitive Landscape
    1. Company Market Share Analysis
    2. Company Profiles
      1. Pfizer Inc.
      2. Azurity Pharmaceuticals, Inc.
      3. Cumberland Pharmaceuticals Inc.
      4. Teva Pharmaceuticals USA, Inc.
      5. Amneal Pharmaceuticals LLC
      6. Sun Pharmaceutical Industries Ltd.
      7. Aurobindo Pharma Limited,
      8. Sandoz Inc
      9. Hikma Pharmaceuticals PLC
      10. Eisai Co., Ltd.
      11. Other prominent players
  15. Global Methotrexate Drug Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
      1. By Type  
        1. >10 mg, 2023-2036F (USD Million)
        2. >15 mg/ml, 2023-2036F (USD Million)
        3. 17.5 mg/ml – 25 mg/ml, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      2. By Disease Type
        1. Cancer, 2023-2036F (USD Million)
          1. Breast Cancer, 2023-2036F (USD Million)
          2. Leukemia, 2023-2036F (USD Million)
          3. Lung Cancer, 2023-2036F (USD Million)
          4. Lymphoma, 2023-2036F (USD Million)
          5. Gestational Trophoblastic Disease, 2023-2036F (USD Million)
          6. Osteosarcoma, 2023-2036F (USD Million)
        2. Autoimmune Diseases, 2023-2036F (USD Million)
          1. Psoriasis, 2023-2036F (USD Million)
          2. Rheumatoid Arthritis, 2023-2036F (USD Million)
          3. Crohn's Disease, 2023-2036F (USD Million)
          4. Others, 2023-2036F (USD Million)
        3. Ectopic Pregnancy, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      3. By Drug Type
        1. Branded, 2023-2036F (USD Million)
        2. Generics, 2023-2036F (USD Million)
      4. By Route Of Administration
        1. Injectable, 2023-2036F (USD Million)
        2. Oral, 2023-2036F (USD Million)
      5. By End User
        1. Hospitals, 2023-2036F (USD Million)
        2. Specialty Clinics, 2023-2036F (USD Million)
        3. Home Healthcare, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      6. By Region
        1. North America, 2023-2036F (USD Million)
        2. Europe, 2023-2036F (USD Million)
        3. Asia Pacific, 2023-2036F (USD Million))
        4. Latin America, 2023-2036F (USD Million)
        5. Middle East & Africa, 2023-2036F (USD Million)
  16. North America Methotrexate Drug Market 2023-2036
    1.  Market Overview
    2. By Value (USD Million)
      1. By Type 
        1. >10 mg, 2023-2036F (USD Million)
        2. >15 mg/ml, 2023-2036F (USD Million)
        3. 17.5 mg/ml – 25 mg/ml, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      2. By Disease Type
        1. Cancer, 2023-2036F (USD Million)
          1. Breast Cancer, 2023-2036F (USD Million)
          2. Leukemia, 2023-2036F (USD Million)
          3. Lung Cancer, 2023-2036F (USD Million)
          4. Lymphoma, 2023-2036F (USD Million)
          5. Gestational Trophoblastic Disease, 2023-2036F (USD Million)
          6. Osteosarcoma, 2023-2036F (USD Million)
        2. Autoimmune Diseases, 2023-2036F (USD Million)
          1. Psoriasis, 2023-2036F (USD Million)
          2. Rheumatoid Arthritis, 2023-2036F (USD Million)
          3. Crohn's Disease, 2023-2036F (USD Million)
          4. Others, 2023-2036F (USD Million)
        3. Ectopic Pregnancy, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      3. By Drug Type
        1. Branded, 2023-2036F (USD Million)
        2. Generics, 2023-2036F (USD Million)
      4. By Route Of Administration
        1. Injectable, 2023-2036F (USD Million)
        2. Oral, 2023-2036F (USD Million)
      5. By End User
        1. Hospitals, 2023-2036F (USD Million)
        2. Specialty Clinics, 2023-2036F (USD Million)
        3. Home Healthcare, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      6. By Country
        1. United States, 2023-2036F (USD Million)
        2. Canada, 2023-2036F (USD Million)
  17. Europe Methotrexate Drug Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
      1. By Type  
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. United Kingdom, 2023-2036F (USD Million)
        2. Germany, 2023-2036F (USD Million)
        3. France, 2023-2036F (USD Million)
        4. Italy, 2023-2036F (USD Million)
        5. Spain, 2023-2036F (USD Million)
        6. Russia, 2023-2036F (USD Million)
        7. Netherlands, 2023-2036F (USD Million)
        8. Rest of Europe, 2023-2036F (USD Million)
  18. Asia Pacific Methotrexate Drug Market 2023-2036
    1.  Market Overview
    2. By Value (USD Million)
      1. By Type  
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. China, 2023-2036F (USD Million)
        2. India, 2023-2036F (USD Million)
        3. Japan, 2023-2036F (USD Million)
        4. South Korea, 2023-2036F (USD Million)
        5. Singapore, 2023-2036F (USD Million)
        6. Australia, 2023-2036F (USD Million)
        7. Rest of Asia Pacific, 2023-2036F (USD Million)
  19. Latin America Methotrexate Drug Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
      1. By Type 
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. Brazil, 2023-2036F (USD Million)
        2. Mexico, 2023-2036F (USD Million)
        3. Argentina, 2023-2036F (USD Million)
        4. Rest of Latin America, 2023-2036F (USD Million)
  20. Middle East & Africa Methotrexate Drug Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
      1. By Type 
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. Israel, 2023-2036F (USD Million)
        2. GCC, 2023-2036F (USD Million)
        3. South Africa, 2023-2036F (USD Million)
        4. Rest of Middle East & Africa, 2023-2036F (USD Million)

Methotrexate Drugs Market Trends

Growth Drivers

  • Increasing Prevalence of Cancer – Methotrexate is commonly used in chemotherapy. It's a treatment for several different types of cancer. Although Methotrexate is not a first-line drug against breast cancer, it might be valuable in fighting the disease due to which the methotrexate drugs market rapidly expanding. According to the World Health Organization (WHO), cancer was the top cause of death globally in 2020, accounting for close to more than 10 million deaths, or about one in every six. The most prevalent types are breast, lung, colon, rectum, and prostate cancers. The second most significant cause of death for women after lung cancer is breast cancer, the most recurring invasive cancer in females.
  • Need for Cost-Effective Medicines- Methotrexate has been on the market for several decades, making it a relatively affordable option compared to newer, more expensive drugs. Its cost-effectiveness has made it a preferred choice for healthcare providers and patients.
  • Increasing Number of Methotrexate Drugs Approvals – The rising number of drug approval is expected to increase the methotrexate drugs market growth. For example, U.S. specialty pharmaceutical company Cumberland Pharmaceuticals Inc. announced the launch of her RediTrex injection in November 2020. RediTrex is a new prefilled syringe specifically designed for precise dosing for subcutaneous administration of methotrexate in patients with rheumatoid arthritis and psoriasis and is easy to use. Besides, in July 2022, The US Food and Drug Administration approved use of methotrexate to lower serum uric acid levels (sUA) in patients with chronic gout.

Challenges

  • Obstruction of Approval of Methotrexate Injection - Due to its drawbacks such as the lengthy development process and stringent regulations, the methotrexate drugs market is facing certain limitations across the world. As methotrexate injection may cause a serious, life-threatening reaction that may occur while or shortly after one receives this medication. Moreover, for individualized prediction of response to methotrexate treatment in patients with RA, clinically useful tools are lacking, which is also a key threat to the market.
  • Lack of Awareness and High Cost of Rheumatoid Arthritis Drugs
  • Side Effects Caused by the Drug

Methotrexate Drugs Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

2.9%

Base Year Market Size (2024)

USD 584.09 million

Forecast Year Market Size (2037)

USD 846.99 million

Regional Scope
  • North America (U.S., and Canada)
  • Latin America (Mexico, Brazil, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, South Korea, Singapore, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, Netherlands, Rest of Europe)
  • Middle East and Africa (Israel, GCC, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF
Browse Key Market Insights with Data Illustration:

Author Credits:  Radhika Pawar


  • Report ID: 2738
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of methotrexate drugs is estimated at USD 597.64 million.

The methotrexate drugs market size was valued at USD 584.09 million in 2024 and is set to exceed USD 846.99 million by 2037, registering over 2.9% CAGR during the forecast period i.e., between 2025-2037. The surge in the prevalence of rheumatoid arthritis and the increasing prevalence of cancer will drive the market growth.

North America industry is set to hold largest revenue share of 41% by 2037, due to rising demand for methotrexate drugs in the region.

The major players in the market include Pfizer Inc., Azurity Pharmaceuticals, Inc., Cumberland Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Sandoz Inc, Hikma Pharmaceuticals PLC, Eisai Co., Ltd.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample